CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Amikacin

阿米卡星 杂质对照品Amikacin Impurities

EP26 个杂质条目26 impurity entries

本页汇总 阿米卡星 的 26 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 26 impurity reference standards of Amikacin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 阿米卡星(Amikacin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA simplified guide for charged aerosol detection of non-chromophoric compounds-Analytical method development and validation for the HPLC assay of aerosol particle size distribution for amikacin
    Journal of pharmaceutical and biomedical analysis · 2017 · Soliven A et al.  ·  PMID 28577419  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and validation of a capillary electrophoresis method with capacitively coupled contactless conductivity detection (CE-C(4) D) for the analysis of amikacin and its related substances
    Electrophoresis · 2012 · El-Attug MN et al.  ·  PMID 22965725  ·  DOI
  3. 杂质研究Impurity studiesLiquid chromatographic determination of amikacin sulphate after pre-column derivatization
    Journal of chromatographic science · 2014 · Korany MA et al.  ·  PMID 24006430  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
    Analytical and bioanalytical chemistry · 2010 · Baietto L et al.  ·  PMID 19898996  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisCharacterization of transposon Tn1528, which confers amikacin resistance by synthesis of aminoglycoside 3'-O-phosphotransferase type VI
    Antimicrobial agents and chemotherapy · 1994 · Lambert T et al.  ·  PMID 8031033  ·  DOI

阿米卡星 —— 原料药与杂质对照品Amikacin — drug substance & impurities

共 27 个条目(含原料药本体)27 items incl. the drug substance
Amikacin structure
EP原料药 APIAPI
阿米卡星Amikacin
Amikacin
CAS No.37517-28-5
Chemical FormulaC22H43N5O13
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity A structure
EPA
硫酸阿米卡星杂质1 (硫酸阿米卡星EP杂质A)Amikacin EP Impurity A
Amikacin EP Impurity A
CAS No.50725-24-1
Chemical FormulaC22H43N5O13
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity A TetraHCl structure
EPA
阿米卡星EP杂质AAmikacin EP Impurity A TetraHCl
Amikacin EP Impurity A TetraHCl
CAS No.—
Chemical FormulaC22H43N5O13.4HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity B structure
EPB
硫酸阿米卡星杂质2(硫酸阿米卡星EP杂质B)Amikacin EP Impurity B
Amikacin EP Impurity B
CAS No.927821-99-6
Chemical FormulaC26H50N6O15
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity B Formate structure
EPB
阿米卡星EP杂质BAmikacin EP Impurity B Formate
Amikacin EP Impurity B Formate
CAS No.—
Chemical FormulaC26H50N6O15.CH2O2
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity C structure
EPC
硫酸阿米卡星杂质3(硫酸阿米卡星EP杂质C)Amikacin EP Impurity C
Amikacin EP Impurity C
CAS No.50725-25-2
Chemical FormulaC22H43N5O13
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity C TetraHCl structure
EPC
阿米卡星EP杂质CAmikacin EP Impurity C TetraHCl
Amikacin EP Impurity C TetraHCl
CAS No.—
Chemical FormulaC22H43N5O13.4HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity D structure
EPD
硫酸阿米卡星杂质4(硫酸阿米卡星EP杂质D)Amikacin EP Impurity D
Amikacin EP Impurity D
CAS No.59-01-8
Chemical FormulaC18H36N4O11
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity E structure
EPE
硫酸阿米卡星杂质5 (硫酸阿米卡星EP杂质E)Amikacin EP Impurity E
Amikacin EP Impurity E
CAS No.50866-72-3
Chemical FormulaC22H43N5O13
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity F structure
EPF
硫酸阿米卡星杂质6(硫酸阿米卡星EP杂质F)Amikacin EP Impurity F
Amikacin EP Impurity F
CAS No.197909-67-4
Chemical FormulaC26H50N6O15
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity G structure
EPG
硫酸阿米卡星杂质7(硫酸阿米卡星EP杂质G)Amikacin EP Impurity G
Amikacin EP Impurity G
CAS No.50896-99-6
Chemical FormulaC22H43N5O13
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity G DiHCl structure
EPG
阿米卡星EP杂质GAmikacin EP Impurity G DiHCl
Amikacin EP Impurity G DiHCl
CAS No.—
Chemical FormulaC22H43N5O13.2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity H structure
EPH
硫酸阿米卡星杂质8 (硫酸阿米卡星EP杂质H)Amikacin EP Impurity H
Amikacin EP Impurity H
CAS No.48237-20-3
Chemical FormulaC22H44N6O12
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin EP Impurity I structure
EPI
硫酸阿米卡星杂质9(硫酸阿米卡星EP杂质I)Amikacin EP Impurity I
Amikacin EP Impurity I
CAS No.40371-51-5
Chemical FormulaC4H9NO3
Purity>95%询价On request
10mg25mg50mg100mg
(R)-4-Amino-2-Hydroxybutyric Acid HCl structure
—
(R)-4-Amino-2-Hydroxybutyric Acid HCl
CAS No.117173-81-6
Chemical FormulaC4H10ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Glucose Adduct 1 structure
—
Amikacin Glucose Adduct 1
CAS No.—
Chemical FormulaC28H53N5O18
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Glucose Adduct 2 structure
—
Amikacin Glucose Adduct 2
CAS No.—
Chemical FormulaC28H53N5O18
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 1 structure
1
硫酸阿米卡星杂质16Amikacin Impurity 1
Amikacin Impurity 1
CAS No.1793053-92-5
Chemical FormulaC16H32N4O9
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 2 TetraHCl (1,3''-Di-HABA Kanamycin A TetraHCl) structure
2
阿米卡星杂质2Amikacin Impurity 2 TetraHCl (1,3''-Di-HABA Kanamycin A TetraHCl)
Amikacin Impurity 2 TetraHCl (1,3''-Di-HABA Kanamycin A TetraHCl)
CAS No.—
Chemical FormulaC26H50N6O15.4HCl
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 3 structure
3
硫酸阿米卡星杂质21Amikacin Impurity 3
Amikacin Impurity 3
CAS No.40371-54-8
Chemical FormulaC10H21N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 4 structure
4
硫酸阿米卡星杂质17Amikacin Impurity 4
Amikacin Impurity 4
CAS No.1793053-90-3
Chemical FormulaC16H32N4O9
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 5 structure
5
异山梨醇杂质19Amikacin Impurity 5
Amikacin Impurity 5
CAS No.154-58-5
Chemical FormulaC6H12O5
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 6 structure
6
硫酸阿米卡星杂质22Amikacin Impurity 6
Amikacin Impurity 6
CAS No.102419-16-9
Chemical FormulaC6H13NO4
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 7 structure
7
奥拉西坦杂质39Amikacin Impurity 7
Amikacin Impurity 7
CAS No.34368-52-0
Chemical FormulaC4H7NO2
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 8 structure
8
阿米卡星杂质8Amikacin Impurity 8
Amikacin Impurity 8
CAS No.—
Chemical FormulaC16H32N4O9
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 9 structure
9
阿米卡星杂质9Amikacin Impurity 9
Amikacin Impurity 9
CAS No.40371-50-4
Chemical FormulaC12H15NO5
Purity>95%询价On request
10mg25mg50mg100mg
Amikacin Impurity 10 structure
10
硫酸阿米卡星杂质10Amikacin Impurity 10
Amikacin Impurity 10
CAS No.60183-25-7
Chemical FormulaC22H42N4O14
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

阿米卡星 —— 研究文献与合成路线Amikacin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 阿米卡星 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Amikacin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A simplified guide for charged aerosol detection of non-chromophoric compounds-Analytical method development and validation for the HPLC assay of aerosol particle size distribution for amikacin
    Soliven A, Haidar Ahmad IA, Tam J, et al. · Journal of pharmaceutical and biomedical analysis · 2017 · 被引 21cited 21
  2. Assay of amikacin in the skin by high-performance liquid chromatography
    Nicoli S, Santi P · Journal of pharmaceutical and biomedical analysis · 2006 · 被引 21cited 21
  3. Corrigendum to "Development of an in-syringe gas-assisted density tunable solidification of floating organic droplet-based dispersive liquid phase microextraction method coupled with HPLC-MS/MS for monitoring amikacin in biological fluids", [J. Pharmaceutical Biomed. Anal., Vol. 210, 2022, 114552]
    Mohebbi A, Jouyban A, Farajzadeh MA, et al. · Journal of pharmaceutical and biomedical analysis · 2023

合成与制备工艺专利Synthesis & process patents

  1. Amikacin paste and preparing method and use
    WANG GUOQIN ZHOU · 公开号 CN1742742CN1742742 · 2006
  2. Method for preparing colon targeted pill of amikacin used for poultry and livestock
    LI XUDONG BAO · 公开号 CN1969866CN1969866 · 2007
  3. Process for the preparation of amikacin precursors
    DALL ASTA LEONE, GAREGNANI EUGENIO · 公开号 US5656735US5656735 · 1997
  4. Process for the preparation of amikacin precursors
    DALL ASTA LEONE, GAREGNANI EUGENIO · 公开号 US5621085US5621085 · 1997
  5. Process for the synthesis of amikacin
    MANGIA ALBERTO · 公开号 US5763587US5763587 · 1998

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

阿米卡星 杂质谱研究要点Amikacin — impurity profiling notes

下面这些是拿到 阿米卡星 的 27 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 27 impurity entries for Amikacin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances